A frameshift mutation in peroxisome-proliferator-activated receptor-γ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367) [2]

Clinical Genetics

Volumn 70, Issue 4, 2006, Pages 360-362

  Hegele, Robert A ^a,b   Ur, C ^c   Ransom, T P ^c   Cao, H ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; VALSARTAN;

AGED; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DISEASE DURATION; DNA BINDING; DNA SEQUENCE; FAMILIAL DISEASE; FAMILIAL PARTIAL LIPODYSTROPHY SUBTYPE 3; FEMALE; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE DELETION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; LETTER; LIPODYSTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIGREE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS;

ADULT; FEMALE; FRAMESHIFT MUTATION; HUMANS; LIPODYSTROPHY, FAMILIAL PARTIAL; PPAR GAMMA;

EID: 33748318070     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2006.00674.x     Document Type: Letter

References (13)

1. Hegele RA. Monogenic forms of insulin resistance: Apertures that expose the common metabolic syndrome. Trends Endocrinol Metab 2003: 14: 371-377.
2. Hegele RA. Phenomics, lipodystrophy, and the metabolic syndrome. Trends Cardiovasc Med 2004: 14: 133-137.
3. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004: 350: 1220-1234.
4. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006: 116: 581-589.
5. Tsai YS, Kim HJ, Takahashi N et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPAR gamma. J Clin Invest 2004; 114: 240-249.
6. Hegele RA, Leff T. Unbuckling lipodystrophy from insulin resistance and hypertension. J Clin Invest 2004: 114: 163-165.
7. Barroso I, Gurnell M, Crowley VE et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999: 402: 880-883.
8. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 2002: 51: 3586-3590.
9. Francis GA, Li G, Casey R et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet 2006: 7: 3.
10. Al-Shali K, Cao H, Knoers N, Hermus AR, Tack CJ, Hegele RA. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab 2004: 89: 5655-5660.
11. Hegele RA. Lessons from human mutations in PPARgamma. Int J Obes Relat Metab Disord 2005: 29: S31-S35.
12. Savage DB, Tan GD, Acerini CL et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003: 52: 910-917.
13. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002: 87: 408-411.